Hespe GE, Nores GG, Huang JJ, Mehrara BJ, et al.
Journal of surgical oncology. Date of publication 2017 Jan 1;volume 115(1):96-98.
1. J Surg Oncol. 2017 Jan;115(1):96-98. doi: 10.1002/jso.24414. Epub 2016 Aug 26.
Pathophysiology of lymphedema-Is there a chance for medication treatment?
Hespe GE(1), Nores GG(1), Huang JJ(1)(2)(3), Mehrara BJ(1).
Author information:
(1)Division of Plastic and Reconstructive Surgery, Department of Surgery,
Memorial Sloan Kettering Cancer Center, New York, New York.
(2)Division of Reconstructive Microsurgery, Department of Plastic and
Reconstructive Surgery, Chang Gung Memorial Hospital, Chang Gung University,
Taoyuan, Taiwan.
(3)Center of the Tissue Engineering, Chang Gung Memorial Hospital, Taoyuan,
Taiwan.
Lymphedema is a common morbid after cancer treatment. The disease characterizes
with progressive inflammatory process that result in irreversible fibrosis. Its
chronology and progressive disease character often impacts the quality of life of
cancer survivors. The pathophysiology of lymphedema remains unclear and the
disease remains non-curable. In this article, we reviewed available studies of
lymphedema and concluded possible treatment strategies for lymphedema. J. Surg.
Oncol. 2017;115:96-98. © 2016 Wiley Periodicals, Inc.
© 2016 Wiley Periodicals, Inc.
DOI: 10.1002/jso.24414
PMID: 27566412 [Indexed for MEDLINE]
